The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus

Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus

(2023) Sung Kyung Cho et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic applications

(2022) Juan Liu et al.   JOURNAL OF AUTOIMMUNITY

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

(2022) Victoria P. Werth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus

(2022) Richard A. Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus

(2021) Jodi L. Karnell et al.   Science Translational Medicine

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus

(2019) Richard Furie et al.   JOURNAL OF CLINICAL INVESTIGATION

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

(2019) Eric F. Morand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

(2017) Richard Furie et al.   Arthritis & Rheumatology

Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases

(2016) Dana Saadeh et al.   EXPERIMENTAL DERMATOLOGY

Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms

(2015) A. Pellerin et al.   EMBO Molecular Medicine

Role for toll-like receptors in autoimmune disease: The example of systemic lupus erythematosus

(2010) Christophe Richez et al.   JOINT BONE SPINE